ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments designed to enhance T cell migration, infiltration and activity into resistant tumour sites, today reports the publication of a paper in the Journal for Immunotherapy of Cancer.
Each year, the EU launches calls for postdoc research fellowships through the Marie Sklodowska-Curie Actions. The prestigious two-year funding of Marie Curie fellowships attracts an enormous number of applications, which makes these fellowships very competitive.
A new VUB spin-off named ABSCINT NV was established. The spin-off is based on technology developed by the joint research efforts of the teams of Prof. Dr. Tony Lahoutte and Prof. Dr. Jo Van Ginderachter at VUB and VIB in Brussels.
VIB is proud today to share V-Bio Ventures' announcement on the first close of their second fund at 78 million euro. V-Bio Fund 2 builds on the success of V-Bio's first fund, with 15 investments in outstanding companies that innovate in healthcare and agriculture.
VIB heeft een aanvraag ingediend voor een nieuwe veldproef met genetisch gewijzigde populieren. De bomen hebben een gewijzigde houtsamenstelling waardoor het hout op een meer efficiënte en meer milieuvriendelijke manier kan worden omgezet naar suikers.
Prof. Dr. Pierre Vanderhaeghen has been awarded the Generet Prize for Rare Diseases for his research into the development of the human brain and ways in which things sometimes go wrong. This prestigious Prize, awarded by the Generet Fund which is managed by the King Baudouin Foundation, is linked to funding with a value of one million euros.
UZ Leuven, KU Leuven researchers and the VIB have examined the immune reaction in COVID-19-patients admitted to the hospital for pneumonia. Detailed analyses of the lung fluid showed new factors that play a role in the excessive immune reactions against the virus in seriously ill patients.
VIB START UP NEWS - Today, Biotalys NV, a transformative food and crop protection company, announces that it has submitted its first protein-based biocontrol, Evoca™, to the Environmental Protection Agency (EPA) in the United States for approval.
An international team of researchers led by Patrik Verstreken at VIB-KU Leuven has succeeded in reversing the effects of Tau, a protein implicated in over 20 different diseases, including Alzheimer’s disease.
Dat de Vlaamse biotechsector in volle expansie is, hoeft geen betoog. Om tegemoet te komen aan deze ontwikkeling bouwt VIB – met PMV als co-financier – een ultramoderne bio-incubator met daarin ook het nieuwe hoofdkantoor van VIB op de nieuwe technologiecampus op Tech Lane Ghent Science Park, campus Eiland.